Revive Therapeutics Ltd. is extending its private placement offering of up to 30,952,381 units at $0.021 per unit, aiming for gross proceeds of $650,000. The first tranche closed in early August, generating $60,900. Each unit includes one common share and one warrant to purchase a share at $0.05 within 36 months. The company plans to use the proceeds for working capital and trade payables. The offering may close in multiple tranches, subject to standard conditions. Revive Therapeutics focuses on developing innovative therapeutics for critical medical needs, including Bucillamine for infectious diseases and nerve agent exposure treatment.

Read more at GlobeNewswire: Revive Therapeutics Announces Extension of Proposed Private